M Iskedjian
Overview
Explore the profile of M Iskedjian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
192
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iskedjian M, Tinmouth A, Arnold D, Deuson R, Isitt J, Mikhael J
J Med Econ
. 2011 Dec;
15(2):313-31.
PMID: 22136485
Objectives: The objective of this study was to obtain utilities, or preference-based quality-of-life values, from the Canadian general public, for potential health states experienced by immune thrombocytopenia (ITP) patients receiving...
2.
Iskedjian M, Walker J, Desjardins O, Robin A, Covert D, Bergamini M, et al.
Curr Med Res Opin
. 2009 Jun;
25(8):1879-88.
PMID: 19530975
Background: The prevalence of open angle glaucoma increases with age, with many patients also receiving medications for non-ocular systemic diseases. Little is known about how systemic medications impact on the...
3.
Iskedjian M, Einarson T
Clin Drug Investig
. 2008 Mar;
16(1):9-18.
PMID: 18370513
Objective: Meta-analyses of efficacy results reported in trials of the pharmacological treatment of gastro-oesophageal reflux disease (GORD) with cisapride, omeprazole or ranitidine were performed using randomised, double-blind studies identified by...
4.
Narine L, Hague L, Walker J, Vicente C, Schilz R, Desjardins O, et al.
Curr Med Res Opin
. 2005 Dec;
21(12):2007-16.
PMID: 16368052
Introduction: Idiopathic pulmonary arterial hypertension (IPAH) is associated with substantial morbidity and mortality. Treprostinil was compared to epoprostenol for the economic impact of treating IPAH patients who failed or were...
5.
Marchetti A, Magar R, Lau H, Murphy E, Jensen P, Conners C, et al.
Clin Ther
. 2002 Jan;
23(11):1904-21.
PMID: 11768842
Background: Attention-deficit/hyperactivity disorder (ADHD) is a common childhood neurobehavioral disorder characterized by inattention, hyperactivity, and impulsivity. Prevalence estimates in elementary school children generally range from 3% to 8%. ADHD is...
6.
Oh P, Iskedjian M, Addis A, Lanctot K, Einarson T
Can J Clin Pharmacol
. 2001 Dec;
8(4):199-206.
PMID: 11743592
The high costs and efficacy of clozapine warrant a systematic pharmacoeconomic evaluation to assess its relative cost-utility compared with that of older antipsychotic therapies. An economic analysis of clozapine consisted...
7.
Joffe R, Iskedjian M, Einarson T, OBrien B, Stang M
Can J Clin Pharmacol
. 2001 Sep;
8(3):146-52.
PMID: 11574897
Objective: To examine the use of fluoxetine in an adult population in Saskatchewan. Methods: All adults in the Saskatchewan health care databases who had begun fluoxetine therapy between January 1992...
8.
Clinical and economic factors in the treatment of behavioural and psychological symptoms of dementia
Hemels M, Lanctot K, Iskedjian M, Einarson T
Drugs Aging
. 2001 Aug;
18(7):527-50.
PMID: 11482746
The prevalence of behavioural and psychological symptoms of dementia (BPSD) exceeds 50%. They cause distress to patients and caregivers, increase resource utilisation of various kinds, and form a high risk...
9.
Iskedjian M, Einarson T, OBrien B, De Serres J, Gold R, Gemmill I, et al.
Pharmacoeconomics
. 2001 Jul;
19(5 Pt 2):551-63.
PMID: 11465300
Objective: Pertussis is a highly contagious infection affecting mainly children. Acellular pertussis vaccines were recently introduced in Canada based on evidence of improved safety and efficacy over whole cell vaccines,...
10.
Einarson T, Kulin N, Tingey D, Iskedjian M
Clin Ther
. 2001 Feb;
22(12):1502-15.
PMID: 11192141
Objective: The purpose of this study was to indirectly quantify and compare the intraocular pressure (IOP)-lowering effects of latanoprost and brimonidine eye drops at baseline and after 3 and 6...